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Abstract
Introduction:  Pseudomonas aeruginosa and  Acinetobacter baumanii are important nosocomial
pathogens with wide intrinsic resistance. However, due to the dissemination of the acquired
resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) and metallo beta-
lactamase (MBL) production, multidrug resistant strains have been isolated more often.
Case presentation: We report a case of a Hungarian tourist, who was initially hospitalized in
Egypt and later transferred to Hungary. On the day of admission PER-1-producing P. aeruginosa,
PER-1 producing A. baumannii, SHV-5-producing Klebsiella pneumoniae and VIM-2-producing P.
aeruginosa isolates were subcultured from the patient's samples in Hungary. Comparing the pulsed-
field gel electrophoresis (PFGE) patterns of the P. aeruginosa strains from the patient to the P.
aeruginosa strains occurring in this hospital, we can state that the PER-1-producing P. aeruginosa and
VIM-2-producing P. aeruginosa had external origin.
Conclusion: This is the first report of PER-1-producing P. aeruginosa,and PER-1-producing A.
baumanii strains in Hungary. This case highlights the importance of spreading of the beta-lactamase-
mediated resistance mechanisms between countries and continents, showing the importance of
careful screening and the isolation of patients arriving from a different country.
Introduction
Pseudomonas aeruginosa and Acinetobacter baumanii are very
important nosocomial pathogens mainly in intensive care
units, being responsible for various types of infections
with more and more limited therapeutic options [1].
The P. aeruginosa have significant intrinsic resistance to
antibiotics [2]. Therefore, the antipseudomonal beta-
lactams such as ticarcillin, piperacillin, ceftazidime,
cefepime, aztreonam, and the carbapenems have an
important therapeutic value. Three mechanisms of beta-
lactam resistance are predominant: production of beta-
lactamases, loss of outer membrane proteins and up-reg-
ulation of efflux pumps. Most strains of P. aeruginosa
which are resistant to third-generation cephalosporins
produce a chromosomally mediated molecular class C
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beta-lactamase, the AmpC enzyme [2]. However, acquired
beta-lactamases encoded by mobile genetic elements are
important resistance mechanism in P. aeruginosa and in
Acinetobacter  spp. as well. Acquired resistance to beta-
lactams can lead to therapeutic failure, especially when it
is associated with resistance to other classes of drugs, such
as aminoglycosides and fluoroquinolones. Among these
enzymes acquired, PER (Pseudomonas  extended resist-
ance), a class A extended-spectrum beta-lactamase (ESBL),
occurring less frequently has clinical importance by con-
ferring resistance to oxyimino beta-lactams [3]. Poor out-
come as a result of infection caused by PER-1 producers
has been reported [4]. The also acquired metallo beta-
lactamases (MBLs) of molecular class B can cause resist-
ance to all beta-lactams except monobactam. The genes of
MBLs are usually part of class I integron together with
gene cassettes encoding resistance genes. Several types of
MBL enzymes have been identified in P. aeruginosa among
which the VIM-type enzymes appear to be the most prev-
alent [5].
Here we report the first detection of PER-producing P. aer-
uginosa, A. baumannii isolates and VIM-producing P. aeru-
ginosa in Hungary from a patient, who was hospitalized in
Egypt and transferred to Hungary. This work illustrates the
dissemination of bacteria carrying PER-type ESBL and
VIM-type MBL enzymes.
Case presentation
In April, 2006 a 53-year-old Hungarian tourist was
involved in a severe terror-attack in Egypt. He was initially
hospitalized because of his burn, mechanical injuries and
sepsis syndrome in Egypt. Five days later he was trans-
ferred in comatose, hypoxic and hypothermic condition
to the Burn Unit of State Health Center, Budapest, Hun-
gary. On the day of admission, bacterial cultures taken
from burn wound. Based on the different colony mor-
phology and antibiotic susceptibility patterns three differ-
ent P. aeruginosa strains – an ESBL-producing P. aeruginosa
(PA1), an imipenem-resistant P. aeruginosa (PA2), an
MBL-producing P. aeruignosa (PA3), were observed and
furthermore ESBL-producing Klebsiella pneumoniae (ESBL-
KP), methicillin-resistant Staphylococcus aureus (MRSA)
and  Enterococcus faecalis (EF) were isolated. Next day
ESBL-producing A. baumanii (ESBL-AB) and PA2 were cul-
tured from the patient's canul. During his hospitalization
from his nose PA1, ESBL-AB, ESBL-KP, MRSA, from his
throat PA1, ESBL-AB, ESBL-KP, from his trachea PA3,
ESBL-AB, ESBL.KP,-MRSA and from his wound PA1, PA3,
ESBL-AB, ESBL-KP, MRSA and EF were isolated. Blood cul-
tures were taken nine occasions and PA1, ESBL-KP, MRSA
and EF were subcultured. The patient received adequate
supportive treatment and empirically cefepime, subse-
quently meropenem and vancomycin were administered
intravenously at high dosage. The aminoglycosides were
synergy resistant. On the 8th day of the hospitalization in
Hungary the patient died.
The isolates were identified by VITEK 2 (BioMérieux,
Marcy l'Etoile, France). On a routine antibiogram synergy
was observed between amoxycillin/clavulanic acid and
cefepime or ceftazidime disks (Oxoid, Basingstoke,
Hampshire, United Kingdom) in K. pneumoniae and in A.
baumanii strains but no synergy was observed in P. aerugi-
nosa  strains. The minimum inhibitory concentrations
(MICs) of the antimicrobial agents were determined by E-
test (AB Biodisk, Solna, Sweden) and by using the inter-
pretative criteria of the Clinical and Laboratory Standards
Table 1: The antibiotic susceptibility of P. aeruginosa, A. baumanii and K. pneumoniae strains.
Antimicrobial agents MIC values (μg/ml)
P. aeruginosa (PA1) P. aeruginosa (PA2) P. aeruginosa (PA3) A. baumanii K. pneumoniae
Ceftazidime > 256 > 256 > 256 > 256 > 256
Ceftazidime/clavulanic acid > 4 > 4 > 4 < 0.64 3
Cefotaxime > 32 > 32 > 32 > 32 > 32
Cefotaxime/clavulanic acid > 1 > 1 > 1 0.23 0.38
Ceftriaxone > 256 > 256 > 256 > 256 > 256
Piperacillin/tazobactam > 256 > 256 > 256 > 256 > 256
Cefepime > 32 > 32 > 32 > 32 > 32
Aztreonam > 64 32 8 > 64 > 64
Imipenem 2 32 > 256 1 1
Imipenem+EDTA 1.5 32 12 1.5 < 1
Meropenem 0.25 1 > 32 0.38 0.25
Amikacin > 256 6 > 256 48 1.5
Gentamicin 16 > 256 > 256 32 > 256
Netilmicin > 32 > 32 2 1 > 32
Tobramycin > 256 > 256 32 32 24
Ciprofloxacin > 32 > 32 > 32 > 32 1Annals of Clinical Microbiology and Antimicrobials 2008, 7:12 http://www.ann-clinmicrob.com/content/7/1/12
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Institute [6]. Pulsed-field gel electrophoresis (PFGE) of
the  SpeI-digested (New England Biolab, Beverly, MA)
genomic DNA of P. aeruginosa was performed and ana-
lyzed as described previously [7]. Isoelectric focusing
(IEF) was performed, as described previously [8]. In the
PCR assays primers specific to blaTEM [9], blaSHV [9], blaPER
[10], blaOXAs [11], blaIMP, blaVIM and blaclassI genes [12] were
used. The nucleotide sequences were determined using
the ABI 3100 Genetic Analyzers (Applied Biosystems, Fos-
ter City, CA). Sequences were analyzed using NCBI BLAST
search.
Three different antibiotic susceptibility patterns were
observed in P. aeruginosa strains isolated from the patient
on the day of admission (Table 1). All of them were resist-
ant to cephalosporins. The PA1 P. aeruginosa strain was
sensitive only to carbapenems, the other P. aeruginosa
strain (PA2) was sensitive only to meropenem and both
PA1 and PA2 were resistant to all the other tested antibi-
otics. The third P. aeruginosa (PA3) strain was sensitive to
aztreonam and netilmicin and resistant to the all cepha-
losporins and carbepenems. However, the imipenem MIC
value decreased in the presence of EDTA from > 256 to 12
μg/ml suggesting the presence of an MBL enzyme. The A.
baumanii isolate was resistant to all cephalosporins and
aztreonam, but the ceftazidime and cefotaxime MIC val-
ues decreased in the presence of clavulanic acid suggesting
the presence of an ESBL enzyme. The K. pneumoniae strain
had also ESBL phenotype based on the MIC values and it
was sensitive to carbapenems, amikacin and ciprofloxacin
as well.
The PCR and sequencing results are summarized in Table
2. TEM-1 genes were identified in A. baumanii and K. pneu-
moniae. OXA genes were recognized in PA1 and PA3
strains. PER-1 genes were found in PA1 and A. baumanii
isolates and SHV-5 was found in K. pneumoniae. Only the
PA3 isolate harbored the VIM-2 gene. The OXA-10 and
VIM-2 genes were located on the same class I integrons, as
the sequencing result of class I integron showed.
According to IEF test results, all the isolates contained β-
lactamases. Isoelectric focusing confirmed the expression
of PER-1 (pI 5.3), TEM-1 (pI 5.4), OXA-1 (pI 7.4), OXA-
10 (pI 6.1), SHV-5 (pI 8.2), VIM-2 (pI 5.3) and the chro-
mosomal AmpC cephalosporinase (pI 8 or > 8.5)
enzymes in the different strains (Table 2).
The three P. aeruginosa isolates, PA1, PA2 and PA3,
showed three different PFGE patterns (data not pre-
sented) suggesting that they belonged to different clones
(Table 2). Comparing these PFGE patterns to six other P.
aeruginosa  strains occurring in this Hungarian hospital
during the same period, no similarity was found suggest-
ing the external origin of PA1, PA2 and PA3.
Discussion
Based on the antibiotic susceptibilities, IEF and the
sequencing result we can state that the PA1 strain and the
A. baumanii strain produced PER-1 ESBL enzyme. The A.
baumanii strain also produced TEM-1 and the PA1 strain
OXA-10 broad-spectrum β-lactamase. The PA2 strain pro-
duced only chromosomal AmpC cephalosporinase as sug-
gesting that loss of OprD was responsible for the
imipenem resistance. The PA3 strain produced the OXA-1
broad-spectrum β-lactamase and the VIM-2 MBL enzyme.
The  K. pneumoniae strain produced SHV-5 and TEM-1
enzyme.
According to the type of ESBL enzyme produced by differ-
ent bacteria species SHV- TEM- and CTX-M type ESBL-pro-
ducing Klebsiella spp. and Escherichia coli strains have been
isolated in Hungary so far [13,14] – while in Egypt the
ESBL phenotype has been observed in K. pneumoniae and
CTX-M-type ESBL in E. coli strains [15,16]. The PER-1
beta-lactamase has been considered to be significant only
in Turkey for years [17]. However, the PER-1 beta-lacta-
mase found mainly in P. aeruginosa has been detected in
many countries such as Turkey, France, Belgium, Spain,
Italy, Poland, Romania, Japan and South Korea until now
[10,18-25]. The PER-1 production in Acinetobacter  spp.
was observed more often in Turkey and in Korea
[4,17,26,27]. According to our knowledge this is the first
report of PER-1-producing P. aeruginosa and PER-1-pro-
ducing A. baumanii in Hungary and since that other strains
of PER-1 producing P. aeruginosa have been isolated [28].
Several types of MBL enzymes – IMP-type, VIM-type, SPM-
1, GIM-1, SIM-1 – have been identified in P. aeruginosa
[5]. The VIM enzymes are the most common in Europe
Table 2: The characteristics of the isolated Gram-negative strains.
TEM PCR SHV PCR PER PCR OXA PCR VIM PCR PFGE pI(s)
P. aeruginosa (PA1) negative negative PER-1 OXA-10 negative A type 5.3, 6.1, 8.0
P. aeruginosa (PA2) negative negative negative negative negative B type 8.0
P. aeruginosa (PA3) negative negative negative OXA-1 VIM-2 C type 5.3, 7.4, 8.0
A. baumanii TEM-1 negative PER-1 negative negative ND 5.3, 5.4, > 8.5
K. pneumoniae TEM-1 SHV-5 negative negative negative ND 5.4, 8.2
ND: not determinedAnnals of Clinical Microbiology and Antimicrobials 2008, 7:12 http://www.ann-clinmicrob.com/content/7/1/12
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[29]. The VIM-2 enzyme detected in this case has been
previously found in several species worldwide and it
seems to be the most prevalent allelic form [30-35]. In
Hungary VIM-producing P. aeruginosa strains have been
isolated but in Egypt MBL-producing strains have not
been reported until now [36,37].
Furthermore the result of the PFGE analysis of the PA1,
PA2 and PA3 confirms, that the three P. aeruginosa strains
– the PER-1 producing P. aeruginosa (PA1), the OprD-loss
P. aeruginosa (PA2) and VIM-2-producing P. aeruginosa
(PA3) strains – had external origin and could be trans-
ferred from Egypt to Hungary. The PER-1 producing P.
aeruginosa and A. baumanii strains disappeared from the
hospital, no more infections have been detected with
these strains since then.
The emergence and subsequently spread of PER-produc-
ing and MBL-producing strains are alarming. Supposing,
that these resistance mechanisms might also exist in other
countries the dissemination of PER-enzyme could be
more prevalent over the world, particularly due to the
unsolved problem of routine screening for ESBL-produc-
tion in P. aeruginosa strains. The CLSI recommendation
for screening the ESBL-production in different bacteria
species is uncomplete, exist just for Klebsiella  spp. and
Escherichia coli strains [6].
In conclusion, this work confirms the emergence of PER-
1-producing P. aeruginosa and A. baumannii isolate, VIM-2
producing P. aeruginosa strains in Hungary. Furthermore it
illustrates the possibility of the inter-country and the
inter-continent spread of the beta-lactamase-mediated
resistance mechanisms. Our study features the interconti-
nental spread of antimicrobial resistance, showing the
importance of careful screening and the isolation patients
arriving from a different country.
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